Ascendis Pharma A/S’s (ASND) Equal Weight Rating Reaffirmed at Morgan Stanley

Morgan Stanley reiterated their equal weight rating on shares of Ascendis Pharma A/S (NASDAQ:ASND) in a research report released on Monday morning, Benzinga reports. Morgan Stanley currently has a $116.00 target price on the biotechnology company’s stock.

Several other equities research analysts have also recently commented on ASND. JPMorgan Chase & Co. lifted their price target on shares of Ascendis Pharma A/S from $165.00 to $167.00 and gave the stock an overweight rating in a research report on Tuesday, April 2nd. Wedbush lifted their price objective on shares of Ascendis Pharma A/S from $207.00 to $225.00 and gave the stock an outperform rating in a research note on Thursday, February 8th. Cantor Fitzgerald reissued an overweight rating and set a $173.00 price objective on shares of Ascendis Pharma A/S in a research note on Thursday, April 18th. Wells Fargo & Company lifted their price objective on shares of Ascendis Pharma A/S from $196.00 to $260.00 and gave the stock an overweight rating in a research note on Friday, March 15th. Finally, Citigroup lifted their price objective on shares of Ascendis Pharma A/S from $146.00 to $182.00 and gave the stock a buy rating in a research note on Thursday, February 8th. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, Ascendis Pharma A/S has an average rating of Moderate Buy and an average target price of $173.25.

Ascendis Pharma A/S Price Performance

Shares of NASDAQ:ASND opened at $142.10 on Monday. Ascendis Pharma A/S has a one year low of $66.03 and a one year high of $161.00. The company has a 50 day moving average of $149.12 and a 200-day moving average of $125.10. The stock has a market cap of $8.27 billion, a price-to-earnings ratio of -15.36 and a beta of 0.50.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings results on Wednesday, February 7th. The biotechnology company reported ($1.66) EPS for the quarter, topping the consensus estimate of ($2.15) by $0.49. Ascendis Pharma A/S had a negative net margin of 180.61% and a negative return on equity of 16,574.15%. The company had revenue of $148.62 million during the quarter, compared to analysts’ expectations of $97.02 million. Equities research analysts anticipate that Ascendis Pharma A/S will post -4.15 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. GAMMA Investing LLC bought a new position in Ascendis Pharma A/S in the fourth quarter valued at approximately $25,000. Private Ocean LLC bought a new stake in shares of Ascendis Pharma A/S in the first quarter worth $36,000. Quadrant Capital Group LLC lifted its position in shares of Ascendis Pharma A/S by 90.4% in the fourth quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 151 shares in the last quarter. EverSource Wealth Advisors LLC lifted its position in shares of Ascendis Pharma A/S by 37.6% in the fourth quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company’s stock worth $42,000 after purchasing an additional 91 shares in the last quarter. Finally, Signaturefd LLC lifted its position in shares of Ascendis Pharma A/S by 31.9% in the third quarter. Signaturefd LLC now owns 798 shares of the biotechnology company’s stock worth $75,000 after purchasing an additional 193 shares in the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.